The European Fair Pricing Network (EFPN) welcomes the Commission’s initiative to revise the EU general pharmaceutical legislation. The EFPN urges the Commission to prioritize the following problems: First, unequal access to affordable medicines for patients EU wide is a great problem that threatens the health and lives of many Europeans.
EFP
European Fair Pricing Network
NGO · Netherlands · EU Transparency Register 193588825276-25
2
positions filed
in the 583 files tracked
2
legislative files
of 583 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 964 non-governmental organisations on this site, they rank #478 by legislative files engaged — a count of participation, not a measure of influence.
1.8
declared lobbying FTE
self-declared
—
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2016
in the register since
Declares membership of
- https://www.kwf.nl/english/pages/default.aspx
- www.efpn.eu
- ECL https://www.europeancancerleagues.org/
- SFP https://smokefreepartnership.eu/
- GVRV https://gezondheidsfondsenvoorrookvrij.nl/
- SGF https://www.gezondheidsfondsen.nl/
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026).
- Register category
- Non-governmental organisations
- Registered as
- KWF Kankerbestrijding (KWF)
- Head office
- Amsterdam, Netherlands
Self-declared to the EU Transparency Register (snapshot 2 Sept 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track European in PolicySpeak: request access →
Work at European Fair Pricing Network? so we know who speaks for it.
Their record over time
European Fair Pricing Network filed 2 positions between 15 Dec 2020 and 22 Apr 2021, across 2 of the 583 legislative files tracked here, attaching a full position paper 1 time.
2020 · 1 filed2021 · 1 filed
What they argued
European Fair Pricing Network - EFPN The European Fair Pricing Network (EFPN) welcomes the Commission’s initiative to seek a new legal framework to solve issues within current legislation on medicines for children and rare diseases. The EFPN urges the Commission to prioritise the following problems: First, there are no approved treatments for 95% of rare diseases. This must change.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put European Fair Pricing Network next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
Showing 5 of 52.
Is this your organization?
Everything on this page comes from European Fair Pricing Network’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.